Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -780,000 | 48% |
| Cost of Revenue | 780,000 | 48% |
| Operating expense | 1.9M | 44.4% |
| Net Income | -2M | 41.8% |
| EBITDA | -1.9M | 44.4% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 300,000 | 88.3% |
| Total Liabilities | 2.4M | 56.3% |
| Shares Outstanding | 4.9M | 72.2% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -4.5M | 171.9% |
| Cash from financing | 2.6M | 58.7% |
EPS
Financial Highlights for Virpax Pharmaceuticals in Q3 '24
Gross Profit stood at -780,000, marking a 48% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 780,000, a -48% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.9M, showing a -44.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2M, showing a 41.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -1.9M, showing a 44.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
